

Disorders Presenting Primarily With Diarrhea

Nicholas E. Kman
Howard A. Werman

REFERENCES

1. Thielman NM, Guerrant RL: Acute infectious diarrhea. *N Engl J Med* 350: 38, 2004.
2. Kroser JA, Metz DC: Evaluation of the adult patient with diarrhea. *Primary Care* 23: 629, 1996.
3. Binder HJ: Pathophysiology of acute diarrhea. *Am J Med* 88 (Suppl 6A): 2S, 1990.
4. Park SI, Giannella RA: Approach to the adult patient with acute diarrhea. *Gastroenterol Clin North Am* 22: 483, 1993.
5. Goodgame R: A Bayesian approach to acute infectious diarrhea in adults. *Gastroenterol Clin N Am* 35: 249, 2006.
6. Savola KL, Baron EJ, Thompkins LS, Passaro DJ: Fecal leukocyte stain has diagnostic value for outpatients but not inpatients. *J Clin Microbiol* 39: 266, 2001.
7. Salam I, Katelaris P, Leigh-Smith S, et al: Randomized trial of single-dose ciprofloxacin for travellers' diarrhoea. *Lancet* 344: 1537, 1994.
8. Hines J, Nachamkin I: Effective use of the clinical microbiology laboratory for diagnosing diarrheal diseases. *Clin Infect Dis* 23: 1292, 1996. [PMID 8953074]
9. Bartlett JG: Antibiotic-associated diarrhea. *N Engl J Med* 346: 334, 2002.
10. Sullivan P: Nutritional management of acute diarrhea. *Nutrition* 14: 758, 1998.
11. DuPont HL: New insights and directions in traveler's diarrhea. *Gastroenterol Clin North Am* 35: 337, 2006.
12. Kamat D, Mathur A: Prevention and management of travelers' diarrhea. *Dis Mon* 52: 289, 2006.
13. de la Cabada Bauche J, Dupont HL: New developments in traveler's diarrhea. *Gastroenterol Hepatol* 7: 88, 2011.
14. de Saussure PH: Management of the returning traveler with diarrhea. *Therap Adv Gastroent* 2: 367, 2009.
15. Riddle MS, Arnold S, Tribble DR: Effect of loperamide in combination with antibiotics on treatment outcomes in traveler's diarrhea: a systematic review and meta-analysis. *Clin Infect Dis* 47: 1007, 2008.
16. Akalin HE: Role of quinolones in the treatment of diarrhoeal diseases. *Drugs* 49 (Suppl 2): 128, 1995.
17. Aserkoff B, Bennett JV: Effect of antibiotic therapy in acute salmonellosis on the fecal excretion of *Salmonellae*. *N Engl J Med* 281: 636, 1969.
18. Ericsson CD, DuPont HL, Mathewson JJ, et al: Treatment of traveler's diarrhea with sulfamethoxazole and trimethoprim and loperamide. *JAMA* 263: 257, 1990.
19. Ouyang-Latimer J, Jafri S, Vantassel A, et al: In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008. *Antimicrob Agents Chemother* 55: 874, 2011.
20. McDonald LC, Killgore GE, Thompson A, et al: An epidemic, toxin gene-variant strain of *Clostridium difficile*. *N Engl J Med* 353: 2433, 2005.
21. DuPont HL, Jiang ZD, Ericsson CD, et al: Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. *Clin Infect Dis* 33: 1807, 2001.
22. Koo HL, DuPont HL, Huang DB: The role of rifamixin in the treatment and chemoprophylaxis of travelers' diarrhea. *Therap Clin Risk Manag* 5: 841, 2009.
23. Allen SJ, Martinez EG, Gregorio GV, Dans LF: Probiotics for treating acute infectious diarrhoea. *Cochrane Database Syst Rev* 11: CD003048, 2010.
24. Dennehy PH: Rotavirus vaccine—an update. *Vaccine* 25: 3137-3141, 2007.
25. Kelly CP: A 76-year-old man with recurrent *Clostridium difficile* associated diarrhea: review of *C. difficile* infection. *JAMA* 301: 954, 2009.
26. Hookman P, Barkin JS: *Clostridium difficile* associated infection, diarrhea, and colitis. *World J Gastroenterol* 15: 1554, 2009.
27. Bartlett JG: Antibiotic-associated diarrhea. *N Engl J Med* 346: 334, 2002.
28. Gerdng DN, Johnson S, Peterson LR, et al: *Clostridium difficile*-associated diarrhea and colitis. *Infect Control Hosp Epidemiol* 16: 459, 1995.
29. Kelly CP, LaMont JT: *Clostridium difficile*—more difficult than ever. *N Engl J Med* 359: 1932, 2008.
30. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB: A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. *Clin Infect Disease* 45: 302, 2007.
31. Louie TJ, Miller MA, Mullane KM, Weis K, et al: Fidaxomicin versus vancomycin for *Clostridium difficile* infection. *N Engl J Med* 364: 422, 2011.
32. Lowy I, Molrine DC, Leav BA, et al: Treatment with monoclonal antibodies against *Clostridium difficile* toxins. *N Engl J Med* 362: 197, 2010.
33. Pillai A, Nelson R: Probiotics for treatment of *Clostridium difficile*-associated colitis in adults. *Cochrane Database Syst Rev* 1: CD004611, 2008.
34. Koo HL, Koo DC, Musher DM, DuPont HL: Anti-motility agents for the treatment of *Clostridia difficile* colitis and diarrhea. *Clin Infect Dis* 48: 606, 2009.
35. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM: Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. *Inflam Bowel Dis* 17: 423, 2011.
36. Schwartz DA, Maltz BE: Treatment of fistulizing inflammatory bowel disease. *Gastroenterol Clin North Am* 38: 595, 2009.
37. Devlin SM, Panaccione M: Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. *Gastroenterol Clinics N Am* 38: 577, 2009.
38. Levine JS, Burakoff R: Extraintestinal manifestations of inflammatory bowel disease. *Gastroenterol Hepatol* 7: 235, 2011.
39. Vermeire S, Van Assche G, Rutgeerts P: Laboratory markers in IBD: useful, magic, or unnecessary toys? *Gut* 55: 426, 2006.
40. Zisman TL, Rubin DT: Novel diagnostic and prognostic modalities in inflammatory bowel disease. *Gastroenterol Clin North Am* 38: 729, 2009.
41. Porter CK, Tribble DR, Aliaga PA, Halvorson HA, Riddle MS: Infectious gastroenteritis and risk of developing inflammatory bowel disease. *Gastroenterol* 135: 781, 2008.
42. Kornbluth A, Sachar DB: Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol* 99: 1371, 2004.
43. Travis SP, Stange EF, Lemann M, et al: European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. *Gut* 55 (Suppl 1): i16, 2006.
44. Dubinsky MC, Hassard PV, Abreu MT, et al: Thioguanine (6-TG): a therapeutic alternative in a subgroup of IBD patients failing 6-mercaptopurine. *Gastroenterology* 118: A891, 2000.
45. Tamboli CP: Current medical therapy for chronic inflammatory bowel diseases. *Surg Clin N Am* 87: 697, 2007.
46. West RL, van der Woude CJ, Hansen BE, Felt-Bersma RJ, van Tilburg AJ, Drapers JA, Kuipers EJ: Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a doubleblind placebo-controlled study. *Aliment Pharmacol Ther* 20: 1329, 2004.
47. Rutgeerts P, Sandborn WJ, Feagan BG, et al: Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 353: 2462, 2005.
48. Schreiber S, Rutgeerts P, Fedorak RN, et al: A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. *Gastroenterology* 129: 807, 2005.